Results 111 to 120 of about 41,075 (183)

Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination

Infectious Diseases and Therapy
Introduction Rare myocarditis and pericarditis cases have occurred in coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccine recipients. Troponin levels, a potential marker of myocardial injury, were assessed in healthy participants before and ...
Timothy E. Albertson, Caitlin Hansen, Smiti Bihari, Juleen Gayed, Xia Xu, J. Abraham Simón-Campos, Michael E. Dever, Jose F. Cardona, Essack Mitha, Jeffrey B. Baker, Georgina Keep, Islamiat Oladipupo, Federico J. Mensa, Ye Feng, Hua Ma, Kenneth Koury, Susan Mather, Claudia Ana Ianos, Annaliesa S. Anderson, Özlem Türeci, Uǧur Şahin, William C. Gruber, Alejandra Gurtman, Charu Sabharwal, Nicholas Kitchin, the C4591031, C4591007 Clinical Trial Groups   +25 more
doaj   +1 more source

Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial

Infectious Diseases and Therapy
Introduction COVID-19 continues to cause substantial health burden, particularly among vulnerable populations. Vaccines remain a vital tool in preventing severe disease outcomes. As the causative pathogen, severe acute respiratory syndrome coronavirus 2 (
Oyeniyi Diya, Juleen Gayed, Francine S. Lowry, Hua Ma, Vishva Bangad, Federico Mensa, Jing Zou, Xuping Xie, Yanping Hu, Mark Cutler, Todd Belanger, David Cooper, Xia Xu, Robin Mogg, Özlem Türeci, Uǧur Şahin, Kena A. Swanson, Kayvon Modjarrad, Annaliesa S. Anderson, Alejandra Gurtman, Nicholas Kitchin   +20 more
doaj   +1 more source

Correction: Boikos et al. Co-Administration of BNT162b2 COVID-19 and Influenza Vaccines in Adults: A Global Systematic Review. <i>Vaccines</i> 2025, <i>13</i>, 381. [PDF]

Vaccines (Basel)
Boikos C, Schaible K, Nunez-Gonzalez S, Welch V, Hu T, Kyaw MH, Choi LE, Kamar J, Goebe H, McLaughlin J.   +9 more
europepmc   +1 more source

Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework [PDF]

INTRODUCTION:The mRNA vaccines mRNA-1273 and BNT162b2 demonstrated high efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in phase 3 clinical trials, including among older adults.
Bausch-Jurken, MT, Beck, E, Green, N, Haeussler, K, Kavikondala, S, Malmenäs, M, Mishra, NK, Nassim, M, Sharma, P, Van de Velde, N, Wang, X   +10 more
core  

Post-vaccination SARS-CoV-2 infections and antibody responses after BNT162b2 in patients with severe obesity: a retrospective cohort study. [PDF]

Front Endocrinol (Lausanne)
Kara Z, Ak T, Demir AN, Akçin R, Dinç HÖ, Taşkın HE, Gareayaghi N, Kocazeybek B, Yumuk VD.   +8 more
europepmc   +1 more source

Four doses of coronavirus disease 2019 vaccination for patients with inborn errors of immunity compared to 3 doses for healthy individuals. [PDF]

J Allergy Clin Immunol Glob
Chan JCH, Cheng SMS, Leung D, Wang X, Wang M, Cheuk YC, Ho C, Tsang LCH, Kwan TC, Lee AMT, Li WY, Lam JHY, Zhang K, Tam IYS, Chan SM, Chan KW, Peiris M, Tu W, Lau YL, Rosa Duque JS.   +19 more
europepmc   +1 more source

Building better antibody responses: The interplay of infection, vaccination, and immune imprinting. [PDF]

PNAS Nexus
Carissa Aurelia L, Selva KJ, Chung AW.
europepmc   +1 more source

mRNA-based SARS-CoV-2 vaccines: intracellular processing and aggregation of the encoded spike protein as a mechanistic contributor to cardiac cellular stress. [PDF]

Front Immunol
Schreckenberg R, Woitasky N, Itani N, Czech L, Windhorst AC, Juchem M, Bär C, Thum T, Ferdinandy P, Schulz R.   +9 more
europepmc   +1 more source

Immune Response to COVID-19 Vaccines: Updates in a Fast-Moving Scenario. [PDF]

Vaccines (Basel)
De Marco F.
europepmc   +1 more source

Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trial. [PDF]

Front Immunol
Batmunkh T, Neal EF, Amraa O, Mazarakis N, Altangerel B, Avaa N, Batbayar L, Batsukh K, Bright K, Burentogtokh T, Do LAH, Dorj G, Hart JD, Jamiyandorj O, Javkhlantugs K, Jigjidsuren S, Justice F, Li S, Mashbaatar K, Moore KA, Namjil N, Nguyen CD, Ochirbat B, Surenjav U, Thomson H, Tsolmon B, Licciardi PV, von Mollendorf C, Mulholland K.   +28 more
europepmc   +1 more source